The EGFR inhibition by erlotinib was found to overcome lenvatinib drug resistance in hepatocellular carcinoma by blocking the activation of the EGFR–STAT3–ABCB1 signaling pathway [74]. The gene discussed is STAT3; the disease is hepatocellular carcinoma.